Cargando…

2759. Cefiderocol vs Best Available Therapy for the Treatment of Carbapenem- Resistant Acinetobacter baumannii

BACKGROUND: Cefiderocol has been evaluated as a treatment of carbapenem-resistant gram negative infections. However robust data for the optimal approach to treat carbapenem-resistant Acinetobacter baumannii (CRAB) is lacking. The purpose of this study was to evaluate the efficacy of cefiderocol vs b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Daisey, Gabrielle N, Vyas, Nikunj M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678626/ http://dx.doi.org/10.1093/ofid/ofad500.2370

Ejemplares similares

523. Dual vs. Triple Antibiotic Therapy for Carbapenem-Resistant Acinetobacter baumannii Infections
por: Markelwith, Justin Patrick, et al.
Publicado: (2019)

Compassionate use of cefiderocol for carbapenem-resistant Acinetobacter baumannii prosthetic joint infection
por: Mabayoje, Diana A, et al.
Publicado: (2021)

2134. Impact of ADC ß-lactamase amino acid variation on cefiderocol (FDC) susceptibility in carbapenem-resistant Acinetobacter baumannii (CRAb) strains
por: Iovleva, Alina, et al.
Publicado: (2023)

In Vitro Activity of Cefiderocol against a Global Collection of Carbapenem-Resistant Acinetobacter baumannii Isolates
por: Seifert, Harald, et al.
Publicado: (2023)

Rapid detection of cefiderocol susceptibility/resistance in Acinetobacter baumannii
por: Raro, Otávio Hallal Ferreira, et al.
Publicado: (2023)

In vitro Activity of Cefiderocol Against Carbapenem-Resistant Acinetobacter baumannii Clinical Isolates: a Single Center Experience
por: Quirino, Angela, et al.
Publicado: (2023)

Acinetobacter baumannii and Cefiderocol, between Cidality and Adaptability
por: Stracquadanio, Stefano, et al.
Publicado: (2022)

597. False Positive Carbapenemase Test in Carbapenem Resistant Acinetobacter baumannii
por: Tao, Lili, et al.
Publicado: (2023)

Efficacy of cefiderocol- vs colistin-containing regimen for treatment of bacteraemic ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii in patients with COVID-19
por: Russo, A., et al.
Publicado: (2023)

Resistance to Cefiderocol Involved Expression of PER-1 β-Lactamase and Downregulation of Iron Transporter System in Carbapenem-Resistant Acinetobacter baumannii
por: He, Yukun, et al.
Publicado: (2022)

636. Genome Epidemiology of Carbapenem-Resistant Acinetobacter baumannii (CRAb) in the United States
por: Iovleva, Alina, et al.
Publicado: (2019)

2158. An outbreak of carbapenem-resistant Acinetobacter baumannii at a tertiary hospital in Ethiopia
por: Adbaru, Mulatu G, et al.
Publicado: (2023)

1447. Cluster of Carbapenem-resistant Acinetobacter baumannii in the Context of Local Community Transmission
por: Darwish, Malik, et al.
Publicado: (2023)

Acinetobacter baumannii response to cefiderocol challenge in human urine
por: Nishimura, Brent, et al.
Publicado: (2022)

2477. Characteristics of patients infected with Carbapenem-resistant Acinetobacter baumannii complex and Carbapenem-resistant Enterobacterales in Tennessee, 2016–2021
por: Patel, Dipen, et al.
Publicado: (2023)

Cefiderocol treatment for carbapenem-resistant Acinetobacter baumannii infection in the ICU during the COVID-19 pandemic: a multicentre cohort study
por: Pascale, Renato, et al.
Publicado: (2021)

1855. Risk factors for early mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia
por: Lee, Chan Mi, et al.
Publicado: (2022)

2557. Development of Rabbit Models of Ventilator-Associated Carbapenem-Resistant Acinetobacter baumannii Pneumonia
por: Petraitis, Vidmantas, et al.
Publicado: (2023)

Cefiderocol for Severe Carbapenem-Resistant A. baumannii Pneumonia: Towards the Comprehension of Its Place in Therapy
por: Rando, Emanuele, et al.
Publicado: (2021)

1273. Efficacy of Cefiderocol against carbapenem-resistant A. baumannii and P. aeruginosa in ventilator-associated pneumonia mouse model
por: Ota, Kenji, et al.
Publicado: (2020)

Navigating Available Treatment Options for Carbapenem-Resistant Acinetobacter baumannii-calcoaceticus Complex Infections
por: Shields, Ryan K, et al.
Publicado: (2023)

Case Report: Successful Rescue Therapy of Extensively Drug-Resistant Acinetobacter baumannii Osteomyelitis With Cefiderocol
por: Dagher, Michael, et al.
Publicado: (2020)

666. Outcomes Using Cefiderocol for the Treatment of Acinetobacter baumannii Infections from the PROVE (Real-World Evidence) Study
por: Marcella, Stephen, et al.
Publicado: (2022)

Education: An overview from the author of ‘Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant Gram-negative infections in intensive care unit patients’
por: Falcone, Marco
Publicado: (2021)

Induced Heteroresistance in Carbapenem-Resistant Acinetobacter baumannii (CRAB) via Exposure to Human Pleural Fluid (HPF) and Its Impact on Cefiderocol Susceptibility
por: Mezcord, Vyanka, et al.
Publicado: (2023)

2759. Immunogenicity of Inactivated Influenza Vaccines Given Early vs. Late After Pediatric Allogeneic Hematopoietic Cell Transplantation
por: Schuster, Jennifer E, et al.
Publicado: (2019)

551. Burden of Illness in Carbapenem-Resistant Acinetobacter baumannii Infections in US Hospitals (2014 to 2018)
por: Pogue, Jason M, et al.
Publicado: (2019)

2137. Real World Experience with Eravacycline for the Treatment of Infections Caused by Carbapenem-Resistant Acinetobacter baumannii
por: Lim, Andy, et al.
Publicado: (2023)

1297. In-Vitro Antibacterial Activities of Cefiderocol (S-649266) Alone and With the Addition of Beta-Lactamase Inhibitors Against Multidrug-resistant Acinetobacter baumannii
por: Abdul-Mutakabbir, Jacinda C, et al.
Publicado: (2020)

1271. Efficacy and Safety of Cefiderocol and Best Available Therapy in Patients with Serious Infections Caused by Carbapenem-Resistant Gram-Negative Infections: Results of the Pathogen-Focused Phase 3 CREDIBLE-CR Study
por: Bassetti, Matteo, et al.
Publicado: (2020)

Voltage-to-time converter MPS 2759
por: Barbalat, O
Publicado: (1965)

1490. Serious Infections Caused by Carbapenem Susceptible and Carbapenem Resistant Acinetobacter baumannii-calcoaceticus Complex - A Retrospective Review
por: Rana, Khurram, et al.
Publicado: (2020)

Colistin, Hot Potato for the Therapy of Carbapenem-resistant Acinetobacter baumannii infections
por: Park, Sang-Won
Publicado: (2019)

135. Clinical and Microbiologic Analysis of Risk Factors for Mortality in Patients with Carbapenem-Resistant Acinetobacter baumannii Bacteremia
por: Cho, Eunbeen, et al.
Publicado: (2019)

548. Carbapenem-Resistant Acinetobacter baumannii Antibiotic Susceptibility Testing and Antibiogram Formation, Connecticut 2017–2019
por: Paranandi, Anu, et al.
Publicado: (2019)

Quantitative proteomics to study carbapenem resistance in Acinetobacter baumannii
por: Tiwari, Vishvanath, et al.
Publicado: (2014)

Carbapenem-resistant Acinetobacter baumannii outbreak at university hospital
por: Takagi, E.H., et al.
Publicado: (2009)

Fanny pack transmission of carbapenem-resistant Acinetobacter baumannii
por: DelleFave, Amber, et al.
Publicado: (2023)

Cefiderocol Versus Colistin for the Treatment of Carbapenem-Resistant Acinetobacter baumannii Complex Bloodstream Infections: A Retrospective, Propensity-Score Adjusted, Monocentric Cohort Study
por: Bavaro, Davide Fiore, et al.
Publicado: (2023)

Comparison between bacteremia caused by carbapenem resistant Acinetobacter baumannii and Acinetobacter nosocomialis
por: Yang, Ya-Sung, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_36rlm1mqqokh6c1dich4bs44od